We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Fusion Antibodies Plc | FAB | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.10 | -2.67% | 3.65 | 12:12:48 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.75 | 3.65 | 3.75 | 3.65 | 3.75 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 02/4/2024 14:56 by beatme1 Yep fab considering delisting needs shareholder vote to agree |
Posted at 02/4/2024 08:38 by beatme1 Hearing fab want to delist following other pharma stocks |
Posted at 27/2/2024 10:31 by troutisout "Fusion Antibodies (FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announced it has received a first purchase order under the master services agreement (MSA) with a leading diagnostics company details of which were announced on 14 February 2024. FAB said reaching this agreement with a world class diagnostics provider positively reinforces the value to the wider commercial world of Fusion Antibodies’ technologies and capabilities. In this case it is the generation of antibodies in diagnostics products.Comment: It could be argued that fundamentally FAB is now on track as a recovery situation, with the purchase order and recent funding. Only a rise in the share price is missing." |
Posted at 14/2/2024 10:14 by jaknife ^^ what clocktower saidI really don't understand why the longs couldn't see this coming. Anyone should be able to do the really basic maths to see that FAB is a sub-scale business that needs a dramatic transformation before it will become profitable. The consequence of it NOT being profitable is that it's loss-making and hence cash-burning and dependent on regular fund raises. They raised £1.56m at 5p in May last year and now have raised £1.38m at 4p. Who will be surprised if they raise another £1.4m a year from now at 3p? You shouldn't be! JakNife |
Posted at 06/2/2024 09:23 by cbeadle It’s crazy that FAB is so lowly valued , the market has not nearly caught up with the improvement in prospects this company has |
Posted at 23/1/2024 16:30 by jaknife I have no particular interest in FAB anymore, it's too small a company. But I would be interested to see any calculations that anyone has done of (a) what FAB's current monthly cash burn is, and (b) therefore what FAB's current cash position is.Do people routinely do these sorts of calculations before investing? JakNife |
Posted at 23/12/2023 12:17 by porky9 Anyone here with solid research can you tell me in layman's terms in relation to the NCI collaboration what they mean by the statement:-“The validation will be run at NCI's laboratories by their staff and antibodies identified pursuant to the Agreement would be retained by NCI” So are they saying, here is our catalogue of antibodies, take your pick, NCI then spend a couple of years R&D on them against diseases they are working on finding cures for, NCI if it goes well find that antibody 1234 is effective against X and on result, it validates that FAB have a useful catalogue of antibodies but the antibody 1234 that works in this example is retained by NCI for drug dev to commercialisation? I’m struggling to work out how FAB would financially benefit here in the event of success? If this was a license deal they would get milestone payments? In this example it looks like NCI get the catalogue for nothing but obviously have cost to R&D with it but it’s retained by NCI on success ??? Anyone care to enlighten me what I’m missing here? |
Posted at 08/12/2023 10:37 by jaknife luckyabbeygale,Look back at the chart for FAB. Can you see that massive fall in the share price in May? From c. 40p to about 6p? That coincided with this RNS when the 5p placing was announced: It's unlikely that the next placing will have such a huge discount. But it's also unlikely that FAB will make it through 2024 without yet another placing. If you disagree then buy, it's your choice and the decision is solely down to you. JakNife |
Posted at 30/11/2023 14:40 by thiopia Googling 'Mammalian Cell Display' brings up the name of a long time academic researcher on the area dating back to 2009 in terms of published research... Mitchell HoGuess who is the Director of the Research on Antibody Engineering (Mammalian Cell Display) at US NCI and on the Fusion Antibodies FAB RNS ? Mitchell Ho !!! I think people are underestimating just how big a deal this could be for FAB US Govt NCI just provides one level of validation but an important on (as well as having a multi-billion budget) but this should lead to lots of Bios and Pharmas also beating a path to FAB's door |
Posted at 28/11/2023 15:25 by andymunchkin superg118 Sep '20 - 11:01 - 217 of 36330 2 1 Tidy FAB is not yet on the map as such but will be in the coming week or so. Most booing in now won;t have adman clue about FAB they will assume big cash needed which is completely wrong. That's what I love about FAB. Very low risk, very big upside... ---- price was 1.2op & itCrashed like crUshed candIes pmsl lYingCnTs |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
